Tandem Diabetes (TNDM) Tops Q2 EPS by 22c, Revenues Beat; Offers FY19 Sales Outlook Above Consensus
Tweet Send to a Friend
Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.03), $0.22 better than the analyst estimate of ($0.25). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
